A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions

NCT02647177

Status	RECRUITING
Sponsor	The University of Texas Health Science Center, Houston
Enrollment	1,000 participants

Key Eligibility Criteria

Inclusion (5)

- Diagnosis of Pancreatic Cystic Lesions (PCLs) or Acute Pancreatitis (AP) or chronic pancreatitis(CP) or Pancreatic Cancer (PC) (any stage/grade) or congenital developmental anomalies of the pancreas.
- Any combination of the diagnoses above.
- Patients must provide written informed consent for the collection of blood specimens for research purposes.
- Patients with PCLs must provide informed consent for collection of excess cyst fluid aspirate remaining after testing for routine standard of care
- Patients with pancreatic Cystic Lesions (PCLs) or AP or CP or PC (any stage/grade) or congenital developmental anomalies of the pancreas undergoing surgery must provide informed consent for collection of surgical specimen

Exclusion (3)

- Patients with co-existing malignancies of other organs (or prior history of such)
- Patients unable to provide informed consent
- Patients unable to complete follow up

Locations (1 total)

The University of Texas Health Science Center at Houston, Houston, Texas, United States